Identification of tumor cells expressing claudin 18
Immunohistochemistry (IHC)
CLDN18
Claudin 18
Claudin 18.2
GPCLDN18
43-14A
ISCLDN18IHC
Special
Attach the green “Attention Pathology” address label (T498) to the outside of the transport container before putting into the courier mailer.
A pathology/diagnostic report and a brief history are required.
Specimen Type: Tissue
Supplies:
-Pathology Packaging Kit (T554)
Collection Instructions: Formalin-fixed, paraffin-embedded tissue block; or 3 unstained glass, "positively charged" slides with 4-microns formalin-fixed, paraffin-embedded tissue
Additional Information: One slide will be stained with hematoxylin and eosin and returned.
Decalcified paraffin embedded tissue Wet/frozen tissue Cytology smears Nonformalin fixed tissue including alcohol-formalin-acetic acid (AFA), 95% ethanol, PREFER fixatives or Zinc formalin Nonparaffin embedded tissue Noncharged slides ProbeOn slides | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Special | Ambient (preferred) | ||
Refrigerated |
Identification of tumor cells expressing claudin 18
Claudin 18 is a member of the claudin protein family that regulates cell adhesion. The claudin-18 isoform 2 (CLDN18.2) serves as a biomarker for gastric and gastroesophageal junction cancer.
An interpretive report will be provided.
An interpretation will be provided. This result should be interpreted in the appropriate clinical context.
This test has been validated for nondecalcified paraffin-embedded tissue specimens fixed in 10% neutral-buffered formalin. Recommended fixation time is between 6 and 48 hours. This assay has not been validated on tissues subjected to the decalcification process or use of alternative fixatives for bone and bone marrow specimens or cell blocks.
Age of a cut paraffin section can affect immunoreactivity. Stability thresholds vary widely among published literature and are antigen dependent. Best practice is for paraffin sections to be cut within 6 weeks.
1. Kubota Y, Kawazoe A, Mishima S, et Al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open. 2023;8(1):100762
2. Cao W, Xing H, Li Y, et Al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res. 2022;10(1):38
3. Pellino A, Brignola S, Riello E, et Al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. J Pers Med. 2021;11(11):1095
4. Arnold A, Daum S, von Winterfeld M, et Al. Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas. Clin Transl Oncol. 2020;22(12):2357-2363
Immunohistochemistry on sections of paraffin-embedded tissue.(Unpublished Mayo method)
Monday through Friday
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
88360
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
CLD18 | CLDN18, SemiQuant IHC, Manual | In Process |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
620666 | Interpretation | 50595-8 |
621004 | Participated in the Interpretation | No LOINC Needed |
621005 | Report electronically signed by | 19139-5 |
621006 | Material Received | 81178-6 |
621007 | Disclaimer | 62364-5 |
621008 | Case Number | 80398-1 |